GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY JR Brown; JA Woyach; K Patel; TA Eyre; Cy Cheah; P Ghia; W Jurczak; P Abada; WG Wierda; GFPN Presenter;

MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR O Al-Sawaf; M Jen; LM Hess; J Zhang; B Goebel; JM Pagel; TA Eyre; LYCGN Presenter;

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES AR Fonseca; CC Justino; VC Molla; PE Yamakawa; IB Rabelo; A Hill; L Arnold; R Kelly; M Griffin; T Munir; E Velloso; T Dalessandro; AM Risitano; P Scheinberg; A Kulasekararaj; C Arrais-Rodrigues;